Your browser doesn't support javascript.
loading
High interobserver and intraobserver reproducibility among pathologists assessing PD-L1 CPS across multiple indications.
Nuti, Shanthy; Zhang, Yiwei; Zerrouki, Nabila; Roach, Charlotte; Bänfer, Gudrun; Kumar, George L; Manna, Edward; Diezko, Rolf; Kersch, Kristopher; Rüschoff, Josef; Jasani, Bharat.
Afiliação
  • Nuti S; Biomarkers and Diagnostics, Oncology, Global Medical and Scientific Affairs, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USA.
  • Zhang Y; Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, USA.
  • Zerrouki N; Biomarkers and Diagnostics, Oncology, Global Medical and Scientific Affairs, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USA.
  • Roach C; Companion Diagnostics, R&D, Agilent Technologies, Inc., Carpinteria, CA, USA.
  • Bänfer G; Discover Biomarker Academy Department, Discovery Biomarker Services GmbH, Targos Molecular Pathology GmbH, Kassel, Germany.
  • Kumar GL; Scientific Affairs, Targos Inc., San Bruno, CA, USA.
  • Manna E; CDx Pathology, Agilent Technologies, Inc., Carpinteria, CA, USA.
  • Diezko R; Discover Biomarker Academy Department, Discovery Biomarker Services GmbH, Targos Molecular Pathology GmbH, Kassel, Germany.
  • Kersch K; Companion Diagnostics, Agilent Technologies, Inc., Carpinteria, CA, USA.
  • Rüschoff J; Department of Pathology, Targos Molecular Pathology GmbH, Kassel, Germany.
  • Jasani B; Department of Pathology, Targos Molecular Pathology GmbH, Kassel, Germany.
Histopathology ; 81(6): 732-741, 2022 Dec.
Article em En | MEDLINE | ID: mdl-35993150
ABSTRACT

AIMS:

A common concern among pathologists scoring PD-L1 immunohistochemical staining is interobserver and intraobserver variability. We assessed the interobserver and intraobserver reproducibility of PD-L1 scoring among trained pathologists using a combined positive score (CPS; tumour cell and tumour-associated immune cell staining). METHODS AND

RESULTS:

Data were collected for 2 years (2017-2019) from 456 pathologists worldwide. Digital training encompassed unique, tumour-specific training, and test sets. Samples were stained using PD-L1 IHC 22C3 pharmDx and evaluated at specific CPS cutoffs for gastric cancer (GC), cervical cancer (CC), urothelial cancer (UC), oesophageal cancer (OC), and head and neck squamous cell carcinoma (HNSCC). Pathologists underwent expert-to-peer training and scored 20 blinded samples on day 1 and 25 blinded samples on day 2 (including 15 of the day 1 samples). Interobserver and intraobserver reproducibility were assessed. For GC (120 observers) and CC (32 observers) samples assessed at CPS ≥1, average interobserver agreement was 91.5% and 91.0%, respectively, and average intraobserver agreement was 90.2% and 96.6%, respectively. For UC (139 observers) and OC (52 observers) samples measured at CPS ≥10, average interobserver agreement was 93.4% and 93.7%, respectively, and average intraobserver agreement was 92.0% and 92.5%, respectively. For HNSCC samples (113 observers), average interobserver agreement was 94.1% at CPS ≥1 and 86.5% at CPS ≥20; intraobserver agreement was 94.7% at CPS ≥1 and 90.5% at CPS ≥20.

CONCLUSION:

The consistently high interobserver and intraobserver concordance rates support the effectiveness of face-to-face training of many global pathologists for scoring PD-L1 CPS across multiple indications at several specific cutoffs.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição / Neoplasias de Cabeça e Pescoço / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Histopathology Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição / Neoplasias de Cabeça e Pescoço / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Histopathology Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos